Wet Age-Related Macular Degeneration (Wet AMD) Market

Market Overview:

The 7 major Wet Age-Related Macular Degeneration (Wet AMD) markets reached a value of US$ 8,997.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 16,864.9 Million by 2034, exhibiting a growth rate (CAGR) of 5.9% during 2024-2034.

Wet Age-Related Macular Degeneration (Wet AMD) market is currently driven by factors such as a rising patient pool, improving diagnosis and drug treatment rates, an increase in the ageing population and improving efficacy of current and emerging therapies, etc. Wet Age-Related Macular Degeneration is an eye disease that destroys the macula, which is part of the retina at the back of the eye. Wet AMD involves the growth of abnormal blood vessels under the macula that leak blood and fluids into layers of the retina, including the macula. The symptoms of wet AMD usually start suddenly and are often severe. If a patient has wet AMD in one eye, it’s extremely likely that he will also get it in the other eye. With wet AMD, leaked blood and fluids can cause scar tissue to form and damage cells in the retina, damaging the central vision. Wet AMD can cause severe vision loss but does not lead to total blindness since a patient can retain his side vision. Having wet AMD can, however, make it extremely hard for people to do their daily things and can negatively impact the quality of their life.

Although the cause of Wet Age-Related Macular Degeneration is still largely unknown, age represents an important risk factor for developing Wet AMD. The disease is most common in people over 50 and becomes even more common in their 70s and 80s. Furthermore, smoking doubles the probability of developing wet AMD. In addition to cutting off oxygen to the eyes, researchers have found that smoking may damage cells and make it more difficult for nutrients to reach the eyes through the bloodstream. Other risk factors include gender, race, family history, heart disease, obesity etc.

IMARC Group’s new report "Wet Age-Related Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Wet Age-Related Macular Degeneration market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Wet Age-Related Macular Degeneration market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Wet Age-Related Macular Degeneration across the seven major markets. According to the report, the United States has the largest patient pool for Wet Age-Related Macular Degeneration and also represents the largest market for Wet Age-Related Macular Degeneration treatments. Furthermore, the current Wet Age-Related Macular Degeneration treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Wet Age-Related Macular Degeneration market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, Current and Future Epidemiology Scenario
• Historical, Current and Future Performance of the Wet Age-Related Macular Degeneration Market
• Historical, Current and Future Performance of Various Therapeutic Categories in the Wet Age-Related Macular Degeneration Market
• Sales of Various Drugs Across the Wet Age-Related Macular Degeneration Market
• Reimbursement Scenario in the Wet Age-Related Macular Degeneration Market

Competitive Landscape:

This report also provides a detailed analysis of the current Wet Age-Related Macular Degeneration marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the Wet Age-Related Macular Degeneration market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
• What was the country-wise size of the Wet Age-Related Macular Degeneration market across the seven major markets in 2023 and how will it look like in 2034?
• What is the growth rate of the Wet Age-Related Macular Degeneration market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the Wet Age-Related Macular Degeneration market?
   

Epidemiology Insights

• What is the size of the Wet Age-Related Macular Degeneration patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) of Wet Age-Related Macular Degeneration across the seven major markets?
• What are the key factors driving the epidemiological trend of Wet Age-Related Macular Degeneration?
• What will be the growth rate of Wet Age-Related Macular Degeneration patients across the seven major markets?
   

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed Wet Age-Related Macular Degeneration drugs and what are their market performance?
• What are the key pipeline Wet Age-Related Macular Degeneration drugs and how are they expected to perform in the coming years?
• How safe are the current marketed Wet Age-Related Macular Degeneration drugs and what are their efficacies?
• How safe are the late-stage pipeline Wet Age-Related Macular Degeneration drugs and what are their efficacies?
• What are the current treatment guidelines for Wet Age-Related Macular Degeneration drugs across the seven major markets?
• Who are the key companies in the Wet Age-Related Macular Degeneration market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Wet Age-Related Macular Degeneration market?